1. P1227: POLATUZUMAB VEDOTIN, RITUXIMAB, AND BENDAMUSTINE COMBINATION IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-WORLD DATA FROM TURKEY. (23rd June 2022) Authors: Dal, M. S.; Uncu Ulu, B.; Uzay, A.; Akay, O. M.; Besisik, S.; Yenerel, M. N.; Celik, S.; Kaynar, L.; Yucel, O. K.; Deveci, B.; Sonmez, M.; Mehtap, O.; Bekoz, H. S.; Sunu, C.; Salim, O.; Ulas, T.; Karti, S.; Altuntas, F.; Ferhanoglu, B.; Firatli Tuglular, T. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P813: EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB. (23rd June 2022) Authors: Yenerel, M. N.; Sicre de Fontbrune, F.; Piatek, C.; Sahin, F.; Füreder, W.; Ogawa, M.; Tomazos, I.; Doll, H.; Ozol-Godfrey, A.; Sierra, J. R.; Szer, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 707 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗